NRG-HN003, “A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC),” is permanently closed to accrual effective immediately because it has reached its accrual target for evaluable patients. 


  • Data collection and site IRB renewal for closed studies must continue until the study is terminated.

See protocol section 9.1.2 for details about drug accountability. Sites must follow PMB’s guidelines for drug destruction and return:

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse